文献速递泌尿生殖与妇科肿瘤放疗

预测局部晚期宫颈癌同步放化疗联合图像引导近距离放疗总生存的列线图:RETRO-EMBRACE研究

Nomogram Predicting Overall Survival in Patients With Locally Advanced Cervical Cancer Treated With Radiochemotherapy Including Image-Guided Brachytherapy: A Retro-EMBRACE Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-04-29

PURPOSE: To present a nomogram for prediction of overall survival (OS) in patients with locally advanced cervical cancer (LACC) undergoing definitive radiochemotherapy including image-guided adaptive brachytherapy (IGABT).…

要点

  • 列线图基于7个AIC筛选因素预测60个月总生存,交叉验证c=0.73。
  • 多因素Cox模型确认FIGO2009分期、淋巴结转移、同步化疗和CTVHRVolumeBT独立显著。
  • 近距离放疗时原发肿瘤状态(CTVHRVolumeBT)是重要结局预测因素。

核心结论

  • 这是首个用于预测接受图像引导近距离放疗的局部晚期宫颈癌患者总生存的列线图。
  • 除年龄、FIGO2009分期、宫体受累、化疗实施、总治疗时间和淋巴结转移外,近距离放疗时原发肿瘤状态似乎是 essential 结局预测因素。
  • 结果有助于个体化治疗调整和治疗期间患者咨询。

研究设计与样本

  • 采用按中心分层的多因素Cox回归模型进行单因素分析,以Akaike信息准则逐步选择预测因素构建列线图,通过一致性概率和校准图进行内部验证。

主要发现

  • 多因素Cox回归模型确认4个因素显著:FIGO Stage2009、淋巴结转移、同步化疗、CTVHRVolumeBT。
  • 预测模型和列线图基于AIC选择的7个因素(年龄、宫体受累、FIGO Stage2009、淋巴结转移、同步化疗、CTVHRVolumeBT、OTT),显示出良好的校准和区分度(交叉验证一致性概率c=0.73)。

关键数值与推荐

  • 列线图预测诊断后60个月的总生存。
  • 最终模型纳入7个因素:年龄、宫体受累、FIGO Stage2009、淋巴结转移、同步化疗、CTVHRVolumeBT、OTT。
  • 内部验证交叉验证一致性概率c=0.73。

临床怎么用

  • 可用于接受同步放化疗联合图像引导自适应近距离放疗的局部晚期宫颈癌患者个体化总生存预测。
  • 有助于治疗期间根据预测因素调整治疗策略和进行患者咨询。
  • 近距离放疗时原发肿瘤状态(CTVHRVolumeBT)应作为重要结局预测指标纳入评估。

局限性

  • 内部验证,未进行外部验证。
  • 回顾性研究设计。
  • 缺失数据占7.2%,采用多重插补处理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To present a nomogram for prediction of overall survival (OS) in patients with locally advanced cervical cancer (LACC) undergoing definitive radiochemotherapy including image-guided adaptive brachytherapy (IGABT). METHODS AND MATERIALS: Seven hundred twenty patients with LACC treated with radiochemotherapy including IGABT in 12 institutions (median follow-up 56 months) were analyzed; 248 deaths occurred. Thirteen candidate predictors for OS were a priori chosen on the basis of the literature and expert knowledge. Missing data (7.2%) were imputed using multiple imputation and predictive mean matching. Univariate analysis with a multivariable Cox regression model for OS stratified by center was performed. Stepwise selection of predictive factors with the Akaike Information Criterion was used to obtain a predictive model and construct a nomogram for OS predictions 60 months from diagnosis; this was internally validated by concordance probability as a measure of discrimination and a calibration plot. RESULTS: Thirteen potential predictive factors were evaluated; 10 factors reached statistical significance in univariate analysis (age, Hemoglobin, FIGO Stage2009, tumor width, corpus involvement, lymph node involvement, concurrent chemotherapy, dose to 90% of the high-risk clinical target volume, volume of CTV at the first brachytherapy [CTVHRVolumeBT], overall treatment time [OTT]). Four factors were confirmed significant within the multivariable Cox regression model (FIGO Stage2009, lymph node involvement, concurrent chemotherapy, CTVHRVolumeBT). The predictive model and corresponding nomogram were based on 7 Akaike Information Criterion-selected factors (age, corpus involvement, FIGO Stage2009, lymph node involvement, concurrent chemotherapy, CTVHRVolumeBT, OTT) and showed promising calibration and discrimination (cross-validated concordance probability c = 0.73). CONCLUSIONS: This is the first nomogram to predict OS in patients with LACC treated with IGABT. In addition to previously reported factors (age, FIGO2009 stage, corpus involvement, chemotherapy delivery, OTT, lymph node involvement), status of primary tumor at the time of brachytherapy seems to be an essential outcome predictor. These results can facilitate individualized tailoring of treatment and patient counseling during the treatment.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Sturdza AE, Pötter R, Kossmeier M, et al. Nomogram Predicting Overall Survival in Patients With Locally Advanced Cervical Cancer Treated With Radiochemotherapy Including Image-Guided Brachytherapy: A Retro-EMBRACE Study. Int J Radiat Oncol Biol Phys. 2021. PMID: 33932530. doi:10.1016/j.ijrobp.2021.04.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。